Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism

Wu-Nan Wu; Linda A. Mckown; Allen B. Reitz

doi:10.1007/bf03190468

journal article Dec 01, 2006

Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism

Wu-Nan Wu Linda A. Mckown Allen B. Reitz

European Journal of Drug Metabolism and Pharmacokinetics Vol. 31 No. 4 pp. 277-283 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf03190468

Topics

No keywords indexed for this article. Browse by subject →

References

15

[1]

Maryanoff, B.E., McComsey, D.F., and Ho, W. ( 1993): 3-Oxopyrido[ 1,2- A]benzimidazole-4-carboxyl and4-oxoazepine [l,2-A]benzimidazole-5-carboxyl derivatives useful for treating central system disorders, US Patent 5,639,760

[2]

Maryanoff, B.E., Ho, W., McComsey, D.F., Reitz, A.B.. Grous, P.P., Nortey, S.O., Shank, R.P., Dubinsky, B., Taylor, Jr., R.J., and Gardocki, J.F. (1995): Potential anxiolytic agents, pyrido[l,2-o]benzimidazole: a new structural class of ligands for the benzodiazepine binding site on GABA-A receptors, J. Med. Chem., 38, 16–20. 10.1021/jm00001a005

[3]

Maryanoff, B.E., McComsey, D.F., Ho, W., Shank, R.P., and Dubinsky, B. (1996): Potential anxiolytic agents — II. Improvement of oral efficacy for the pyrido[ 1,2-α]benzimidazole (PBI) class of GABA-A receptor moderators, Bioorg. Med. Chem Lett., 6, 333–338. 10.1016/0960-894x(96)00025-x

[4]

Maryanoff, B.E., Nortey, S.O., McNally, J.J., Sanfilippo, P.J., McComsey, D.F., Dubinsky, B., Shank, R.P., and Reitz, A.B. (1999): Potential anxiolytic agents: 3. novel A-ring modified pyrido[1,2-α]benzimidazole, Bioorg. Med. Chem. Lett., 9, 1547–1552. 10.1016/s0960-894x(99)00240-1

[5]

Reitz, A.B., Jordan, A.D., Sanfilippo, P.J., and Vaouyios-Smith, A. (1998): US Patent, 5,817,668,6.

[6]

Scott, M.K., Demeter, D.A., Nortey, S.O., Dubinsky. B., Shank, R.P., and Reitz, A.B. (1999): 4 New directions in anxiolytic drug research, Prog. Med. Chem., 36, 169–200. 10.1016/s0079-6468(08)70047-x

[7]

Jordan, A.D., Vaidya, A.H., Rosenthal, D.I., Dubinsky, B., Kordik, C.P., Sanfilippo, P.J., Wu, W. N., and Reitz, A.B. (2002): Potential anxiolytic agents, part 4: novel orally-active N5-substituted pyrido[l,2-α]benzimidazoles with high GABA-A receptor affinity, Bioorg. Med. Chem. Lett., 12, 2381–2386. 10.1016/s0960-894x(02)00463-8

[8]

Dubinsky, B., Vaidya, A.H., Rosenthal, D.I., Hochman, C, Crooke, J.J., Deluca, S., Devine, A., Cheo-Isaacs, CT., Carter, A.R., Jordan, A.D., Reitz, A.B., and Shank, R.P. (2002): 5-Ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahy droben zo[4,5]imidazo[1,2α]-pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), anew nonbenzodiazepine anxiolytic, J. Pharmacol. Exp. Ther, 303, 777–790. 10.1124/jpet.102.036954

[9]

Wu, W.N., McKown, L.A., and Takacs, A.R. (1998): In vitro metabolism of the anxiolytic agent, RWJ-53050, in rat and human hepatic S9 fractions, The 12th Inter. Sympos. on Microsom. and Drug Oxidat., Abstract No. 108.

[10]

Wu, W.N., McKown, L.A., Streeter, A.J., Takacs, A.R., and Reitz, A.B. (1998): Identifcation of metabolites and the cytochrome P450isoforms responsible for the metabolism of an anxiolytic agent, RWJ-53050, in human microsomes, The 12th Inter. Sympos. on Microsom. and Drug Oxidat., Abstract No. 107.

[11]

Wu, W.N., McKown, L.A., and Reitz, A.B. (2001): In vivo metabolism of the anxiolytic agent, RWJ-53050, in the dog, The 6th Internat.ISSX Meeting, Abstract No. 242, Drug Metab. Rev, 33, 123.

[12]

Wu, W.N., McKown, L.A., Melton, J.L., and Reitz, A.B. (2003): In vitro metabolism of the new anxiolytic agent, RWJ-50172, in rat hepatic S9 fraction and microbial transformation in fungi, Cunninghamella sp., J. Pharm, and Pharmacol., 55, 1099–1105. 10.1211/002235703322277122

[13]

Wu, W.N., McKown, L.A., and Reitz, A.B. (2003): in vitro metabolism of the new anxiolytic agent. RWJ-52763, in human hepatic s9 fraction — api-ms/ms identification of metabolites, J. Pharm, and Biomed. Analy., 31, 95–102. 10.1016/s0731-7085(02)00597-6

[14]

Wu, W.N., McKown, L.A., and Reitz, A.B., (2004): Human hepatic metabolism of the anxiolytic agent, RWJ-51521 —api-ms/ms identification of metabolites, Europ. J. Drug Metab. and Pharmacok., 29, 257–262. 10.1007/bf03190608

[15]

Wu, W.N., McKown, L.A., and Reitz, A.B. (2004):: Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic s9 fractions, and in rats, dogs and humans, Europ. J. Drug Metab. and Pharmacok., 29, 263–268. 10.1007/bf03190609

Metrics

3

Citations

15

References

Details

Published: Dec 01, 2006
Vol/Issue: 31(4)
Pages: 277-283
License: View

Authors

Cite This Article

Wu-Nan Wu, Linda A. Mckown, Allen B. Reitz (2006). Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism. European Journal of Drug Metabolism and Pharmacokinetics, 31(4), 277-283. https://doi.org/10.1007/bf03190468

Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism

You May Also Like